Leukemia is an overarching time period encompassing a number of subtypes of blood cancers. Blood cells are produced within the bone marrow, the spongy materials inside bones. The bone marrow incorporates immature stem cells that develop and mature to change into purple blood cells, platelets, or several types of white blood cells.
When mutations happen in bone marrow stem cells, it will probably intrude with the physique’s regular manufacturing of blood cells. This could begin as a illness or dysfunction categorised as a pre-leukemia state (and should or might not progress to leukemia), or it will probably begin as leukemia.
Fadi Haddad, M.D., assistant professor of Leukemia, walked us by means of just a few updates in leukemia analysis being offered on the 2024 American Society of Scientific Oncology Annual Assembly (ASCO).
Oral use of a recognized drug to deal with myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a pre-leukemia state. Haddad explains, “Myelo means associated to the bone marrow, and dysplasia means irregular development. So, in sufferers with MDS, the bone marrow is irregular. If left untreated, it might progress to acute myeloid leukemia (AML).”
Azacitidine is permitted as a remedy for MDS. “It’s given both as an intravenous (IV) infusion, or it is given as subcutaneous injections, which means beneath the pores and skin,” says Haddad. Each choices may very well be inconvenient for some sufferers. “The IV infusion requires sufferers to return to the hospital repeatedly so long as they’re receiving the remedy. The subcutaneous injections could be achieved at residence, however they’ll trigger hematomas and ache within the pores and skin on the web site of the injection.” Compounding the inconvenience, sufferers might obtain the remedy for a number of months or years.
In a examine (Summary 6509) offered by Guillermo Garcia-Manero, M.D., professor of Leukemia, researchers regarded on the security and efficacy of taking azacitidine orally, relatively than through infusion or injection, for sufferers with low- or intermediate-risk MDS. Whereas azacitidine taken orally is permitted for upkeep remedy in sufferers with AML in remission, it isn’t at the moment permitted for the remedy of MDS.
The examine discovered that oral supply of azacitidine had unwanted side effects much like what we’ve seen with oral azacitidine in earlier research. The preliminary efficacy of the drug was additionally good. “Near 30% of sufferers noticed hematologic enchancment, which helps the continued analysis of oral azacitidine in low- or intermediate-risk myelodysplastic syndrome,” Haddad notes.
An investigational drug for acute myeloid leukemia (AML) remedy
One space of curiosity in AML analysis is refining remedy each for older sufferers who want decrease depth remedy and for sufferers with AML that has come again (relapsed) or will not be responding to remedy (refractory). The present normal of care is a mix of the drug venetoclax with both azacitidine or decitabine.
“We have been investigating a number of compounds which might be added to one among these mixtures,” Haddad notes. A examine (Summary 6511) offered by Maro Ohanian, D.O., affiliate professor of Leukemia, seems on the preliminary outcomes of a scientific trial combining normal venetoclax and decitabine remedy with a brand new drug known as BP1001. “Including BP1001 is meant to boost the most cancers cell sensitivity to chemotherapy, so the impact of the chemotherapy shall be stronger,” says Haddad.
The examine checked out this three-drug mixture in older sufferers with newly identified AML in addition to in sufferers of all ages with relapsed or refractory AML. “This triplet mixture was safely administered to sufferers in each teams with out new or sudden toxicities,” Haddad summarizes. “The examine is continuous enrollment and can broaden to enroll extra sufferers to gather knowledge on efficacy.”
Analyzing security issues for bone marrow transplants following remedy of AML with a recognized compound
One other remedy choice for some subtypes of AML is a drug known as gemtuzumab ozogamicin (GO). GO is a sort of molecule referred to as an antibody drug conjugate. Which means two components make up GO: an antibody that attaches to a biomarker on most cancers cells and a chemotherapy drug. “After we give sufferers this type of remedy, the antibody attaches to the leukemia cell, and the drug enters the leukemia cell and results in its dying,” Haddad explains.
The Meals and Drug Administration (FDA) permitted GO in 2017, however there have been issues about unwanted side effects for sufferers who take GO and later obtain bone marrow transplants. “One of many unwanted side effects that we should always take note of is hepatotoxicity — destructive impacts to the liver. In uncommon instances, it will probably trigger hepatic veno-occlusive illness, or VOD. It is a very severe situation that may result in liver failure if left untreated,” says Haddad. Sufferers who take GO could also be at a better danger of growing VOD after they go on to obtain bone marrow transplants.
To research these security issues, Partow Kebriaei, M.D., professor of Stem Cell Transplantation, led a multi-center effort to gather and analyze knowledge (Summary 6516) from grownup sufferers with AML who acquired GO and went on to bear bone marrow transplantation. “The charges of VOD and the charges of mortality are much like sufferers who received a transplant however didn’t take GO,” says Haddad. “This implies the drug didn’t add a lot toxicity in comparison with what we see with out the drug, and GO seems to be secure to be used.”
Elements in myelofibrosis outcomes, remedies for persistent lymphocytic leukemia, and extra
Two different analysis talks come from William Wierda, M.D., Ph.D., professor of Leukemia, and Julie Braish, M.D., a fellow in Leukemia. Wierda led the CAPTIVATE Part II scientific trial (Summary 7009). This trial regarded on the mixture of venetoclax and ibrutinib in sufferers with persistent lymphocytic leukemia and small lymphocytic lymphoma. Braish, working with Lucia Masarova, M.D., assistant professor of Leukemia, examined elements affecting outcomes in sufferers with myelofibrosis, one other pre-leukemia state (Summary 6514). These elements embody the variant allele frequency of the JAK2 gene mutation and the presence or absence of cytopenias (decrease than regular blood cell counts).
Along with these displays, MD Anderson researchers are giving two different oral displays and quite a few posters on leukemia analysis on the 2024 American Society of Scientific Oncology Annual Assembly. “Our displays at ASCO symbolize the affect our analysis is having in pushing a very broad vary of leukemia and pre-leukemia analysis and remedy ahead,” says Haddad.
Find out about analysis careers at MD Anderson.
